|
1
|
Burhans WC and Heintz NH: The cell cycle
is a redox cycle: linking phase-specific targets to cell fate. Free
Radic Biol Med. 47:1282–1293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shapiro GI: Cyclin-dependent kinase
pathways as targets for cancer treatment. J Clin Oncol.
24:1770–1783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ruetz S, Fabbro D, Zimmermann J, Meyer T
and Gray N: Chemical and biological profile of dual Cdk1 and Cdk2
inhibitors. Curr Med Chem Anticancer Agents. 3:1–14. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stark GR and Taylor WR: Control of the
G2/M transition. Mol Biotechnol. 32:227–248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han SJ and Conti M: New pathways from PKA
to the Cdc2/cyclin B complex in oocytes: Wee1B as a potential PKA
substrate. Cell Cycle. 5:227–231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Cárcer G, Pérez de Castro I and
Malumbres M: Targeting cell cycle kinases for cancer therapy. Curr
Med Chem. 14:969–985. 2007.PubMed/NCBI
|
|
7
|
Abbas T and Dutta A: p21 in cancer:
intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brown L, Boswell S, Raj L and Lee SW:
Transcriptional targets of p53 that regulate cellular
proliferation. Crit Rev Eukaryot Gene Expr. 17:73–85. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boulaire J, Fotedar A and Fotedar R: The
functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol.
48:190–202. 2000.PubMed/NCBI
|
|
10
|
Cazzalini O, Scovassi AI, Savio M, Stivala
LA and Prosperi E: Multiple roles of the cell cycle inhibitor
p21(CDKN1A) in the DNA damage response. Mutat Res. 704:12–20. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lou Z and Chen J: Mammalian DNA damage
response pathway. Adv Exp Med Biol. 570:425–455. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krysko DV, Vanden Berghe T, D’Herde K and
Vandenabeele P: Apoptosis and necrosis: detection, discrimination
and phagocytosis. Methods. 44:205–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sinclair A, Yarranton S and Schelcher C:
DNA-damage response pathways triggered by viral replication. Expert
Rev Mol Med. 8:1–11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schwartz GK and Shah MA: Targeting the
cell cycle: a new approach to cancer therapy. J Clin Oncol.
23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Raucher D, Moktan S, Massodi I and Bidwell
GL III: Therapeutic peptides for cancer therapy. Part II - cell
cycle inhibitory peptides and apoptosis-inducing peptides. Expert
Opin Drug Deliv. 6:1049–1064. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hainaut P: The tumor suppressor protein
p53: a receptor to genotoxic stress that controls cell growth and
survival. Curr Opin Oncol. 7:76–82. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maddika S, Ande SR, Panigrahi S,
Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E
and Los M: Cell survival, cell death and cell cycle pathways are
interconnected: implications for cancer therapy. Drug Resist Updat.
10:13–29. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wani MC, Taylor HL, Wall ME, Coggon P and
McPhail AT: Plant antitumor agents. VI The isolation and structure
of taxol, a novel antileukemic and antitumor agent from Taxus
brevifolia. J Am Chem Soc. 93:2325–2327. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Steed H and Sawyer MB: Pharmacology,
pharmacokinetics and pharmacogenomics of paclitaxel.
Pharmacogenomics. 8:803–815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jassem J, Carroll C, Ward SE, Simpson E
and Hind D: The clinical efficacy of cytotoxic agents in locally
advanced or metastatic breast cancer patients pretreated with an
anthracycline and a taxane: a systematic review. Eur J Cancer.
45:2749–2758. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Montana M, Ducros C, Verhaeghe P, Terme T,
Vanelle P and Rathelot P: Albumin-bound Paclitaxel: the benefic of
this new formulation in the treatment of various cancers. J
Chemother. 23:59–66. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Trudeau ME: Docetaxel: a review of its
pharmacology and clinical activity. Can J Oncol. 6:443–457.
1996.PubMed/NCBI
|
|
23
|
Pienta KJ: Preclinical mechanisms of
action of docetaxel and docetaxel combinations in prostate cancer.
Semin Oncol. 28:S3–S7. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Horwitz SB: Mechanism of action of taxol.
Trends Pharmacol Sci. 13:134–136. 1992. View Article : Google Scholar
|
|
25
|
Donaldson KL, Goolsby GL, Kiener PA and
Wahl AF: Activation of p34cdc2 coincident with
taxol-induced apoptosis. Cell Growth Differ. 5:1041–1050. 1994.
|
|
26
|
Liu Y, Bhalla K, Hill C and Priest DG:
Evidence for involvement of tyrosine phosphorylation in
taxol-induced apoptosis in a human ovarian tumor cell line. Biochem
Pharmacol. 48:1265–1272. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang BR, Kim H, Nam SH, Yun EY, Kim SR,
Ahn MY, Chang JS and Hwang JS: CopA3 peptide from Copris
tripartitus induces apoptosis in human leukemia cells via a
caspase-independent pathway. BMB Rep. 45:85–90. 2012.
|
|
28
|
Jang JY, Kim MK, Jeon YK, Joung YK, Park
KD and Kim CW: Adenovirus adenine nucleotide translocator-2 shRNA
effectively induces apoptosis and enhances chemosensitivity by the
down-regulation of ABCG2 in breast cancer stem-like cells. Exp Mol
Med. 44:251–259. 2012. View Article : Google Scholar
|
|
29
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann
Hematol. 84:627–639. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Widłak P: The DFF40/CAD endonuclease and
its role in apoptosis. Acta Biochim Pol. 47:1037–1044. 2000.
|
|
31
|
Higuchi Y: Chromosomal DNA fragmentation
in apoptosis and necrosis induced by oxidative stress. Biochem
Pharmacol. 66:1527–1535. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lazebnik YA, Kaufmann SH, Desnoyers S,
Poirier GG and Earnshaw WC: Cleavage of poly(ADP-ribose polymerase
by a proteinase with properties like ICE. Nature. 371:346–347.
1994. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyashita T, Krajewski S, Krajewska M,
Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor
suppressor p53 is a regulator of bcl-2 and bax gene expression
in vitro and in vivo. Oncogene. 9:799–805.
1994.PubMed/NCBI
|
|
34
|
Rodriguez I, Ody C, Araki K, Garcia I and
Vassalli P: An early and massive wave of germinal cell apoptosis is
required for the development of functional spermatogenesis. EMBO J.
16:2262–2270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang C, Willingham MC, Reed JC, Miyashita
T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G and Bhalla
K: Highlevels of p26BCL-2 oncoprotein retard
taxol-induced apoptosis in human pre-B leukemia cells. Leukemia.
8:1960–1169. 1994.
|
|
36
|
Strasser A, Harris AW, Jacks T and Cory S:
DNA damage can induce apoptosis in proliferating lymphoid cells via
p53-independent mechanisms inhibitable by Bcl-2. Cell. 79:329–339.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Negrini M, Sabbioni S, Haldar S, Possati
L, Castagnoli A, Corallini A, Barbanti-Brodani G and Croce CM:
Tumor and growth suppression of breast cancer cells by chromosome
17-associated functions. Cancer Res. 54:1818–1824. 1994.PubMed/NCBI
|
